About Us - Shoreline Biosciences
We are passionate about delivering novel therapies to patients in need by harnessing our cutting-edge approach in cellular immunotherapy. We are building a pipeline of iPSC-derived natural killer cell (iNK) and macrophage (iMACs) cellular immunotherapy candidates derived from our deep expertise in iPSC differentiation, genetic engineering and immune cell biology. We are developing the next generation of cellular immunotherapies designed to bring safe, effective and affordable treatments to patients in need through our intelligently engineered, homogenous and scalable off-the-shelf products enabled by our iNK and iMACs cellular immunotherapy platforms. Potter has over 25 years of experience leading people and culture, human capital management and talent management for companies in biotech, biopharma and high technology. Avanzi is a physician-scientist and expert in immuno-oncology and adoptive T cell therapy. Yu is the founder, CEO and CIO of Ally Bridge Group, a leading global life science-dedicated investment group. Yu also advised leading global institutions on their China and Asia strategies and transactions. Yu has founded, launched and managed multiple funds covering venture, growth, buyout and hedge fund investing from China to U.S.
This company is:
Verified
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies - Shoreline Biosciences
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a Shoreline to acquire Editas Medicine’s iNK cell franchise, including EDIT-202 and certain related manufacturing technologies Economics to Editas Medicine to include upfront payment, and development […]
Verified
Shoreline Biosciences Announces Oral Presentation on iPSC-Derived NK Cell (iNK) Platform at Innate Killer Summit Meeting 2022 - Shoreline Biosciences
San Diego, Calif., March 28, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage platforms (iMACs), today announced that management will deliver an oral presentation at the Innate Killer Summit 2022 meeting taking place […]
Verified
Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022) - Shoreline Biosciences
SAN DIEGO, May 10, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced that it will present two posters at the 19th Meeting of the Society for Natural Immunity (NK2022), taking place May […]
View all products
Keywords
Industries
City: San Diego
State: California
Country: United States
Where is Shoreline Biosciences located?
The company Shoreline Biosciences is located in San Diego, California, United States. It's worth noting that the company may has more corporate locations
How many employees does Shoreline Biosciences approximately have?
As of the latest available information Shoreline Biosciences has around 11-50 employees worldwide.
When was Shoreline Biosciences founded?
Shoreline Biosciences was founded in 2020
In which industries does Shoreline Biosciences mainly work?
The company Shoreline Biosciences has it's main focus in the industries of Biotechnology
What is the current company status of Shoreline Biosciences?
Based on the founding year and the amount of employees the company Shoreline Biosciences seems to be a Startup at the current state. Note that over time that status can change
Atara Biotherapeutics
United States
251-500 Employees
2012
View
Nkarta Therapeutics
United States
11-50 Employees
2015
View
Catamaran Bio
United States
11-50 Employees
2020
View
Cue Biopharma
United States
11-50 Employees
2014
View
CoImmune
United States
1-10 Employees
View
ImmuneCyte Inc.
United States
51-100 Employees
View
MiNK Therapeutics
United States
11-50 Employees
2017
View
Legend Biotech
United States
101-250 Employees
2014
View
Topics which have been searched by others and may be interesting for you:
